Investigation on irbesartan combined with low molecular weight heparin in the treatment of COPD patients with pulmonary hypertension
10.3760/cma.j.issn.1008-6706.2012.04.016
- VernacularTitle:厄贝沙坦联合低分子肝素治疗慢性阻塞性肺疾病并肺动脉高压探讨
- Author:
Sijian DENG
;
Xiaofeng WU
;
Xiaoqin LI
;
Guizhen CHEN
- Publication Type:Journal Article
- Keywords:
Irbesartan;
Low molecular weight heparin;
Pulmonary hypertension
- From:
Chinese Journal of Primary Medicine and Pharmacy
2012;19(4):511-512
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical effect,the changes of pulmonary hypertension,serum D-dimer and side effect of irbesartan combined with low molecular weight heparin in the treatment of pulmonary hypertension in COPD patients.Methods 49 patients of COPD were randomly allocated into two groups:the control group( n =22 )and the treatment group( n =27).The patients of the control group were treated with common treatments,for the treatment group,irbesartan 80mg qd combined with low molecular weight heparin 0.4ml IH bid were additionally administered for 14 days.To evaluate the clinical effect,the changes of pulmonary hypertension,serum D-dimer and side effects.Results The treatment group and the control group could reduce the pulmonary artery pressure.The clinical effects of the former were statistically significant better than the control(P ＜0.01 ).Side effect had no statistically significant difference between two groups.Conclusion Irbesartan combined with low molecular weight heparin have better clinical effects in the treatment of pulmonary hypertension in COPD patients and it was convenient,safe and worthy of extending in clinic.
